TD Cowen analyst Dan Brennan initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $32 price target The firm sees additional share upside as it expects Caris to post “superior” sales growth and EBIT margin expansion. This should support a a premium multiple, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences initiated with an Overweight at JPMorgan
- Caris Life Sciences initiated with a Buy at BofA
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating